Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Withdrawn Phase 3 Interventional

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

ClinicalTrials.gov ID: NCT06904274

Public ClinicalTrials.gov record NCT06904274. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 6:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Open Label, Randomized Parallel Group Study Evaluating the Proportion of Women With Complete Resolution of Nonatypical Endometrial Hyperplasia Treated With Mirena or Oral Medroxyprogesterone Acetate for 6 Months

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Researchers are looking for a better way to treat women with nonatypical endometrial hyperplasia (NAEH). Endometrial hyperplasia is a condition where the lining of the uterus (called the endometrium) becomes too thick. Nonatypical means that the condition is not cancerous. It is often caused by hormone imbalances in women. Symptoms can include abnormal vaginal bleeding or irregular periods. If this condition is not treated, then it may lead to cancer. Currently, there are no approved treatments for NAEH and that is why there is still an unmet medical need. The study treatment, Mirena (also known as BAY 865028), is already available as a type of birth control device. It is inserted into the uterus where it gradually releases progesterone. In this study, researchers want to find out if Mirena works for women with NAEH. They believe it can help by keeping hormone levels balanced in the body. The main purpose of this study is to show that uterine lining goes back to completely normal lining after treatment with Mirena and that its use is safe in this population. For this, the researchers will compare the number of participants with benign endometrium after 6 months of treatment with Mirena or oral MPA. The study participants will be randomly assigned into one of two treatment groups. The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA). Based on their group, participants will receive Mirena, which is inserted into the uterus at the start of the study, or they will take progestins once daily by mouth for 6 months. Each participant will be in the study for around 10 months with up to 5 visits to the study clinic/site. Participants will visit the study clinic: * once before the treatment starts * 3 times with a gap of 3 months between the visits during the treatment * then 1 more time after the treatment ends During the study, the doctors and their study team will: * check participant's health by performing tests such as blood and urine tests * perform vaginal ultrasound and hysteroscopy. Hysteroscopy is a minor surgical procedure where a thin camera will be inserted into the womb to check for any abnormality. Sampling of the endometrial lining (cells in the womb) will be done with a thin tube at the same time. * take samples of womb (endometrial) lining * ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.

Study identification

NCT ID
NCT06904274
Recruitment status
Withdrawn
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bayer
Industry
Enrollment
Not listed

Conditions and interventions

Interventions

Combination Product · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 23, 2025
Primary completion
Jun 16, 2026
Completion
Jun 16, 2026
Last update posted
Jul 29, 2026

2025 – 2026

United States locations

U.S. sites
22
U.S. states
14
U.S. cities
22
Facility City State ZIP Site status
Velocity Clinical Research - Phoenix Phoenix Arizona 85006
Cornerstone Clinic for Women - Aldersgate Little Rock Arkansas 72205
Alliance Clinical West Hills West Hills California 91307
Sweet Hope Research Specialty, Inc. - Hialeah Hialeah Florida 33016
New Age Medical Research Corp. Miami Florida 33186
Entrust Clinical Research Palmetto Bay Florida 33176
Emerald Coast Clinical Research Panama City Florida 32405
Paramount Research Solutions | College Park Location Atlanta Georgia 30327
Office of Dr. Cindy Basinski, LLC Evansville Indiana 47715
Velocity Clinical Research - Lafayette Lafayette Louisiana 70508
Southern Clinical Research Associates Metairie Louisiana 70001
Omni Fertility and Laser Institute Shreveport Louisiana 71118
Revive Research Institute - Michigan - Women's Health Dearborn Heights Michigan 48127
Bosque Women's Care | Albuquerque, NM Albuquerque New Mexico 87109
Unified Women's Clinical Research - Centre OB/GYN Raleigh North Carolina 27607
Lyndhurst Clinical Research Winston-Salem North Carolina 27103
ClinOhio Research Services, LLC. | Columbus, OH Columbus Ohio 43213
OB/GYN Associates of Erie Erie Pennsylvania 16507
Chattanooga Medical Research, LLC. | Chattanooga, TN Chattanooga Tennessee 37412
Discovery Clinical Trials - Dallas Dallas Texas 75230
Biopharma Informatic - West Houston Houston Texas 77043
AIH Research- Broadway Pearland Texas 77584

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06904274, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 29, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06904274 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →